Gene Therapy Product QA Documentation May Become Key IND Element - FDA
Executive Summary
Manufacturing quality assurance documentation could become a key component of gene therapy IND submissions, FDA Cellular & Gene Therapies Division Director Philip Noguchi, MD, suggested April 5.